- Since 1970, Abbott’s FreeStyle Libre has been named “Best of the Best” during the Prix Galien Golden Jubilee Awards
- Revolutionary FreeStyle Libre technology transforms the lives of approximately 4.5 million people1 Diabetes in the world
Abbott ParkSick., October 28 February 2022 /PRNewswire/ — The Galien Foundation, the world’s premier institution dedicated to honoring life science innovators, named Abbott’s FreeStyle Libre® Continuous Glucose Monitoring Technology Named “Best Medical Technology” of the Past 50 Years at its Prix Galien Awards October 27 exist New York City. The Garing Golden Jubilee Award recognizes the global innovation that has had the greatest impact on society since the Garing Foundation was established in 1970.
Winners were selected in five categories from 250 products that received Prix Galien between 1970 and 2019, an award considered the equivalent of the Nobel Prize for biopharmaceutical and medical technology research. FreeStyle Libre system awarded 2019 Prix Galien U.S. Best Medical Technology Award.
“Abbott’s FreeStyle Libre portfolio revolutionizes the lifestyle of people with diabetes, eliminating the need for traditional fingertips,” said Jared Watkins, senior vice president of Abbott’s diabetes care business. “Today, approximately 4.5 million people around the world use this life-changing technology to manage their diabetes and improve their health, helping them lead fuller, healthier lives every day.”
“The Prix Galien Awards honor the global ‘best of the best’ innovations that have improved the human condition over the past 50 years,” said Bruno Cohen, President of the Garian Foundation. “The companies behind these amazing innovations have a bold passion for change, which has led to the development of life-saving products.”
Over the years, Abbott has received 11 Prix Galien Awards for innovation in pharmaceuticals and medical technology, including Humira, MitraClip™ and FreeStyle Libre.
Abbott is a global leader in healthcare, helping people live more fully at all stages of life. Our portfolio of life-changing technologies spans healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generics. Our 113,000 colleagues serve people in more than 160 countries.
Connect with Abbott at www.abbott.com, LinkedIn www.linkedin.com/company/abbott, Facebook www.facebook.com/Abbott and Twitter @AbbottNews.
INDICATIONS AND IMPORTANT SAFETY INFORMATION
FreeStyle Libre 14 Day System: Failure to use the FreeStyle Libre 14 Day System in accordance with label directions may result in missed serious hypoglycemic or hyperglycemic events and/or treatment decisions that could result in injury. If readings do not match symptoms or expectations, use the meter’s fingertip values to make treatment decisions. Seek medical attention when appropriate, or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety information.
FreeStyle Libre 2 and FreeStyle Libre 3 systems: Using the FreeStyle Libre 2 or FreeStyle Libre 3 system not in accordance with label directions may result in missed serious hypoglycemic or hyperglycemic events and/or treatment decisions that could lead to injury. If blood sugar alerts and readings do not match symptoms or expectations, use the meter’s fingertip values to make treatment decisions.Seek medical attention when appropriate, or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety information.
Important US Safety Information for MitraClip is available at http://abbo.tt/MitraClipG4ISI.
1 Archived data, Abbott Diabetes Care. Data is based on the number of global users of the FreeStyle Libre product portfolio compared to the number of users of other leading personal use, sensor-based glucose monitoring systems.
2 Archived data, Abbott Diabetes Care. Finger pricks are required to make treatment decisions when you see the “Check Blood Sugar” symbol, symptoms do not match system readings, suspect readings may be inaccurate, or develop symptoms that may be caused by high or low blood sugar.